Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer

A group of cancer research experts are teaming up to launch Affini-T Therapeutics, which aims to develop cancer treatments using T cell receptor (TCR) cancer immunotherapy. TCR involves engineering T cells to recognize and mount a destructive immune response
against tumor cells in patients, potentially targeting a wider range of tumor types than more conventional CAR T cell therapies.

Affini-T will be headquartered in Boston with a research lab located in Seattle. The company is headed by an elite team including CEO and co-founder Jak Knowles, formerly of Metagenomi, Fred Hutch’s head of immunology Philip Greenberg, Fred Hutch Research Associate Thomas Schmitt and Aude Chapuis, Associate Professor at Fred Hutch.

READ THE STORY at GeekWire »